" "
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Rosetta Genomics Executes Credentialing Agreements With Two National Healthcare Preferred Provider Networks

Published: Monday, September 09, 2013
Last Updated: Monday, September 09, 2013
Bookmark and Share
Adds approximately 44 million potential covered lives for the Rosetta Cancer Origin Test.

Rosetta Genomics Ltd. announces that the Company has executed credentialing agreements with FedMed, Inc. (FedMed) and Fortified Provider Network Inc. (FPN) for Rosetta's Cancer Origin Test™.
FedMed is a Preferred Provider Organization (PPO) with over 550,000 physicians, 4,000 hospitals and 60,000 Ancillary Care Providers nationwide. It is estimated that more than 40 million Americans have access to FedMed's National Provider Network. FPN is a national direct-contracted preferred provider network that represents approximately four million covered lives. FPN's select provider network is utilized by self-funded employer groups, insurance carriers and regional and local provider networks that process end-user patient claims.

"Rosetta now has executed credentialing agreements with four national U.S. PPOs. Together with Medicare reimbursement, we estimate that the total number of potential covered lives for which the Cancer Origin Test could be adjudicated as 'in-network' exceeds 100 million," said Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. "We continue to pursue additional agreements with other PPOs as they provide faster payment while maintaining acceptable levels of reimbursement, and also reduce costs incurred through appealing denials. This has become increasingly important to our company as we have expanded our U.S. commercial operations and continue to process and bill a growing number of samples.

"These agreements further validate the clinical utility and improved patient outcomes of our Cancer Origin Test and underscore the importance of determining the tumor origin in hard-to-diagnose metastatic cancers, and Cancers of Unknown or Uncertain Primary (CUP). We believe the Cancer Origin Test can help physicians to accurately diagnose tumor origin in order to optimize treatment. The availability and accuracy of our Cancer Origin Test underscores why uncertainty in cancer diagnosis is no longer acceptable," Mr. Berlin added.

A PPO is a managed care organization of medical doctors, hospitals and other health care providers that has covenanted with an insurer or a third-party administrator to provide health care at reduced rates to the insurer's or administrator's clients. Credentialing is a process whereby provider organizations such as physicians, care facilities and ancillary providers (including testing service providers such as Rosetta Genomics) contract directly with the PPO.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Rosetta Genomics to Acquire PersonalizeDx
Rosetta will gain proprietary tests in prostate, bladder and lung cancer.
Monday, April 13, 2015
Rosetta Genomics and Moffitt Cancer Center Enter into Strategic Alliance
Leverages strengths of both organizations to develop diagnostic assays for important, unmet needs in cancer.
Friday, September 05, 2014
Rosetta Genomics Expands Management Team
Brings extensive track record in leading commercial teams and driving revenues in microRNA, oncology and thyroid diagnostics.
Tuesday, August 26, 2014
Rosetta Genomics, Moffitt Cancer Center Enter mRNA-Based Cancer Diagnostic Agreement
Partnership to advance the development and commercialization of Rosetta's thyroid neoplasia assay.
Tuesday, June 10, 2014
Rosetta Genomics to Receive U.S. Patent for Oncology Therapeutic
Company receives a Notice of Allowance from the USPTO for a patent claiming Mp53-negative cancer patients.
Thursday, February 27, 2014
Rosetta Genomics Appoints Kevin Watson
Recognized expert in healthcare policy and reimbursement to lead payer efforts for Company's line of microRNA diagnostics.
Thursday, February 20, 2014
Study Validating miRview Lung Assay Published in Journal of Molecular Diagnostics
Assay shown to accurately differentiate between the four main types of lung cancer.
Wednesday, July 11, 2012
Rosetta Genomics Announces Compliance with Continued Listing Requirements of The NASDAQ Capital Market
Company is in compliance with the $2.5 million stockholders' equity requirement for continued listing on The NASDAQ Capital Market®.
Thursday, June 07, 2012
Rosetta to Raise $2.2 Million in Registered Direct Offering
Company has entered into agreements with investors to purchase an aggregate of 632,057 ordinary shares at a price of $3.50 per share.
Friday, May 18, 2012
Rosetta Announces $1.75 Million Debt Financing and Potential $1.25 Million Licensing Transaction
Pursuant to the terms of the transaction, Rosetta has also agreed to negotiate in good faith a definitive license agreement with a designee of the holders of the debentures.
Friday, January 27, 2012
Rosetta Genomics Sells Ownership in Rosetta Green
The diagnostics developer announced that it has entered into a Share Transfer Agreement with certain purchasers, pursuant to which it has sold all of the ordinary shares of Rosetta Green Ltd. ("Rosetta Green") it held.
Monday, December 19, 2011
Rosetta Genomics Announces New York State Approval for miRview mets²
Proprietary microRNA diagnostic for identification of cancer of unknown primary now available in all 50 U.S. states.
Friday, December 09, 2011
microRNAs Shown as Biomarkers for Heart Failure Prognosis
Research shows that elevated serum levels of specific microRNAs identify systolic heart failure (HF) patients and correlate with important clinical prognostic parameters.
Tuesday, November 29, 2011
Rosetta Genomics Announces Changes to Board of Directors
Kenneth A. Berlin, President and CEO of Rosetta Genomics, has stepped down from the Company's Board of Directors.
Monday, April 04, 2011
Rosetta Genomics Receives Grant and Joins Rimonim Pharmaceutical Consortium
Consortium aimed to bring Israeli biotechnology companies together to promote RNAi-based therapeutics which is funded by the Office of the Israeli Chief Scientist.
Wednesday, January 12, 2011
Scientific News
‘Smelling’ Prostate Cancer
A research team from the University of Liverpool and the University of the West of England (UWE Bristol) has reached an important milestone towards creating a urine diagnostic test for prostate cancer that could mean that invasive diagnostic procedures that men currently undergo eventually become a thing of the past.
Criminal Justice Alcohol Program Linked to Decreased Mortality
Institute has announced that in the criminal justice alcohol program deaths dropped by 4.2 percent over six years.
Charting Kidney Cancer Metabolism
Changes in cell metabolism are increasingly recognized as an important way tumors develop and progress, yet these changes are hard to measure and interpret. A new tool designed by MSK scientists allows users to identify metabolic changes in kidney cancer tumors that may one day be targets for therapy.
Individuals' Medical Histories Predicted by their Noncoding Genomes
Researchers have found that analyzing mutations in regions of the genome that control genes can predict medical conditions such as hypertension, narcolepsy and heart problems.
'Molecular Movie' Opens Door to New Cancer Treatments
An international team of scientists led by the University of Liverpool has produced a 'structural movie' revealing the step-by-step creation of an important naturally occurring chemical in the body that plays a role in some cancers.
Advancing Synthetic Biology
Living systems rely on a dizzying variety of chemical reactions essential to development and survival. Most of these involve a specialized class of protein molecules — the enzymes.
Preparing for Potential Zika Outbreaks
Experts at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) are developing tools to monitor the spread of the Zika virus and are conducting research to gather more solid data to better assess the risks associated with the infection.
What do Banana Peels and Human Skin Have in Common?
Human skin and banana peels have something in common: they produce the same enzyme when attacked. By studying fruit, researchers have come up with an accurate method for diagnosing the stages of this form of skin cancer.
Biomarker for Recurring HPV-Linked Oropharyngeal Cancers
A look-back analysis of HPV infection antibodies in patients treated for oropharyngeal (mouth and throat) cancers linked to HPV infection suggests at least one of the antibodies could be useful in identifying those at risk for a recurrence of the cancer, say scientists at the Johns Hopkins University.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!